Apellis (APLS) Pharmaceuticals announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately. Wheeler has more than 30 years of leadership experience across the biopharmaceutical industry.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $41 from $44 at BofA
- Needham healthcare analysts hold analyst/industry conference call
- Apellis price target raised to $31 from $30 at Scotiabank
- Promising Outlook for Apellis Pharmaceuticals: Buy Rating Backed by Key Milestones and Attractive Valuation
- Apellis announces FDA acceptance, priority review of sNDA for EMPAVELI